

ALLENEX AB (PUBL)

INTERIM REPORT JANUARY - JUNE 2015

For the April-June period

- Net sales for the period were SEK 33.9 million (31.5).
- Operating income (EBIT) for the period was SEK 4.2 million (2.0).
- Operating margin for the period was 12 percent (6).
- Earnings after tax for the period were SEK 0.4 million (0.4).
- Earnings per share for the period, basic and diluted, were SEK 0.00 (0.00).

For the January-June period

- Net sales for the period were SEK 67.6 million (62.1).
- Operating income (EBIT) for the period was SEK 10.0 million (6.2).
- Operating margin for the period was 15 percent (10).
- Earnings after tax for the period were to SEK 5.9 million (1.6).
- Earnings per share for the period, basic and diluted, were SEK 0.05 (0.01).

Significant events in the second quarter and after the balance sheet date.

- No significant events occurred in the second quarter or after the balance sheet date.

President and CEO Anders Karlsson's comments on the first six-months of 2015

"Sales and profitability in the company continue to grow and over the first six months of the year we have been seeing continued improvement in our operating margin, now at 15 percent (10). Operating income (EBIT) amounted to SEK 4.2 million (2.0) in the second quarter, and to SEK 10.0 million (6.2) for the first half of the year. It is gratifying to see such strong performance in the U.S, where sales were up 29 percent in the second quarter in local currency. The extensive efforts we focused on the American market in 2014 are now bearing results, with sales increasing across the board for the company's product portfolio. We now look forward with confidence to the launch of our new product QTYPE™, based on Real-Time PCR methodology, which will commence in the second half of 2015."

For more information please contact:

Anders Karlsson, CEO, tel: +46 (0) 70-918 00 10 or e-mail: anders.karlsson@allenex.se


Yvonne Axelsson, CFO, tel: +46 (0)8-508 939 72 or e-mail: yvonne.axelsson@allenex.se

GROUP OPERATIONS

Allenex is a life science company that develops, manufactures, markets and sells products on the global market that facilitate safer transplantation of blood stem cells and organs. Allenex is listed on NASDAQ OMX Stockholm, Small Cap, (ticker: ALNX). There are 56 employees in the Allenex group.

SALES

Net sales for the second quarter were SEK 33.9 million (31.5), corresponding to an increase of 8 percent compared to the same period last year.




Sales in North America were up 29 percent in local currency (USD) in the second quarter compared to the same period last year. Sales in North America for the period accounted for 32 percent of Allenex total sales, while the corresponding figure for the second quarter 2014 was 26 percent. Growth in this region is primarily driven by new customers in the SBT segment.

Sales in Europe were down 11 percent in local currency compared to the second quarter 2014, which was unusually strong. In France, the upturn in sales continued, in particular sales of traditional SSP products, where the company's local representative is linked to a national tender process. Germany is showing negative developments for the period, falling by four percent. The transplantation scandal that came to light in 2012 continues to have a negative impact on organ donations in the country. At the same time, we see a consolidation of operations to larger laboratory groups and the transition to more automated technologies such as SSO and SBT.

Sales in the emerging markets of India and China for the quarter were lower than the same period last year.

Sales distribution - global Q2 2015



Allenex products are distributed via direct sales through a proprietary sales organization in key markets such as the USA, Germany and in the Nordic region. They are also distributed via partnerships with local distributors in other markets. Registration processes are ongoing for the company's products in a number of countries, with work underway to secure strong local sales/distribution partners in these markets.

CUSTOMER GROUPS

Allenex customers largely constitute laboratories active in transplantation diagnostics. Today, there are three different technologies on the market for HLA typing (SSP, SSO and SBT), where the most common typing technique globally, in terms of volume, is SSO. However, most laboratories use SSP typing, either as a primary or supplementary technique. The size of the laboratory and its level of automation determines to what extent the respective technologies are used. Today, the largest laboratories mainly utilize automated solutions (SBT and SSO) as their primary technology, while smaller laboratories generally prefer SSP typing. Subsequently, the choice of typing technology is a key parameter for customer categorization.

Furthermore, in recent years two new further-developed technologies have been tested. These are Next Generation Sequencing (NGS), which primarily targets laboratories that conduct register typing, and Real-Time PCR (also called qPCR), which mainly used for typing deceased donors prior to an organ transplant. To date, these two technologies are used on a limited scale, however usage is expected to increase in the coming years. It is believed that NGS will primarily compete with SSO and SBT, while Real-Time PCR is expected to mainly compete with SSP and SSO.

All large Allenex competitors offering automated SSO or SBT solutions, such as Thermo Fischer (comprising One Lambda and Life Technologies), as well as Abbott Laboratories, also provide SSP products.

Allenex is also working to meet market demand for automated typing solutions, in part through proprietary product development, and in part through partnerships with other companies. Since mid-2011, Allenex is the exclusive global distributor of the HLA typing product SBT Resolver™, with the related software Assign-SBT™ from the Australian company Conexio Ge-

nomics. SBT Resolver™ was introduced by Allenex in the second half of 2011. This contract gives Allenex greater opportunity to partner with larger, automated laboratories. Since these laboratories to a large extent strive to use the same supplier for all HLA typing products, this contract will also facilitate increased sales opportunities for Allenex SSP products. SBT Resolver™ has been introduced to a large number of potential customers. Following an introductory demonstration, the laboratory usually conducts an independent comparison to the product currently in use. If the comparison favors Allenex, careful product validation is then carried out prior to fully converting to SBT Resolver™.

The validation process tends to be relatively long, usually taking from 6 to 15 months. At the period end, 41 laboratories had converted, partially or fully, to SBT Resolver™ (22 in North American and 19 in Europa/Asia), with around 20 laboratories at the validation stage.

Abbott Laboratories recently sold the rights to its SBT portfolio to the Dutch company GenDx, which will take over the production and distribution of these products from the end of the year. It is believed that GenDx will thereby be able to strengthen its product portfolio in Europe, while Allenex sees opportunities to further expand its market share for SBT Resolver™ in the USA.

MARKET PERFORMANCE

Allenex initial strategy has been to introduce SBT Resolver™ to the largest and most automated HLA laboratories in the U.S. and Europe, to then, in a second phase, to focus on converting mid-sized laboratories from competing products. A number of the largest laboratories have very high volumes as they conduct tests for national or regional typing registers. Major register typing laboratories conduct HLA typing tests on more than 5,000 individuals per year and are very careful in their evaluation of new suppliers.

In the U.S., in particular, there are larger laboratories where SBT typing is used for clinical typing. In total, around 70 of the 200 HLA laboratories use SBT technology clinically, and of these, 22 laboratories (around 31 percent) have so far chosen Allenex as SBT supplier. Of the 70 laboratories that use SBT technology, around 10 - 15 of them type over 1,500 tissue samples each per year, with a few typing more than that. These are the laboratories that Allenex has initially chosen to target, as they hold high value as reference customers, which is important in this segment. Among these large laboratories, Allenex currently has four customers. In Europe, the trend is that larger laboratories or consortiums of laboratories are becoming more active. This is the case in particular in Germany, where a few really large laboratories are taking a more extensive hold of the typing market. There, the demand is for automated solutions that can handle larger volumes, and during the year Allenex entered into an agreement with a large new customer encompassing the delivery of reagents for SBT typing to this laboratory. This laboratory is one of the very largest in HLA

typing in Europe, entailing not only an increase in volumes but also a well-reputed reference center for Allenex.

The distribution agreement between Conexio Genomics and Allenex subsidiary Olerup SSP AB runs through April 2018. In addition to the distribution of SBT Resolver™, the agreement with Conexio Genomics includes two new products for Next Generation Sequencing (NGS), reagents and software. Also included is Gamma Type™, a product for typing of the Gamma block, an area that has not previously been possible to analyze using traditional methods. The introduction of Gamma Type™ began during the first six months of 2015 and Allenex plans to successively introduce the NGS portfolio over the next two years. The new products will provide Allenex with further opportunity to reinforce its leading position in the HLA typing market.

PRODUCT DEVELOPMENT

Today, Allenex SSP products have a strong market position in their field of technology. They are updated on an ongoing basis and the strategy is to offer as close to total solutions as possible. Continuous product development is carried out to enable the company to maintain its market-leading position in SSP technology. Allenex continues to develop the existing product line to secure high performance SSP typing. The company is also reviewing solutions adapted for laboratories looking for SSP technology with the possibility of attaining a higher degree of automation, which can be used as a complement to the SSO and SBT techniques. In 2012, Allenex introduced the Allenex Olerup SSP® Add-ons, as a complement to automated techniques (SSO and SBT). In 2014, Olerup SSP® introduced more products in an effort to meet customer needs for improved HLA typing using traditional SSP technology.

During 2014, active development began on a completely new product group for HLA typing based on Real-Time PCR (q-PCR) methodology. The starting point for the development work is SSP technology, which is at the core of the Allenex product range today. The new product QTYPE™ will primarily focus on low-resolution typing in conjunction with organ transplantation and typing that either requires ease of administration and expedient results, or where the resolution requirements are lower, such as in a family-investigation prior to stem cell transplantation.

QTYPE™ will initially compete with traditional SSP typing, a sector where Allenex has products today, but also with SSO. In the SSP segment, the company counts on being able to challenge other suppliers and win market share. Great opportunity to win market share is also seen in the SSO segment, where One Lambda is dominant today. When transplanting organs from deceased donors it is of great importance to be able to expediently carry out HLA typing to find an appropriate recipient. Real-Time PCR is a more automated method that provides faster results with a lesser proportion of manual work. Typing with QTYPE™ will take around one hour compared to the up to three hours it takes to do traditional SSP typing. In this context, SSO typing is relatively slow, taking 5-7 hours to conduct. Be-

sides organ transplantation, the method has applications in other types of conditions. QTYPE™ was introduced at the end of April at the European HLA congress, EFI, in Geneva. It is currently estimated that the new product will be ready for launch in the second half of 2015.

SIGNIFICANT EVENTS IN THE GROUP

Significant events in the first quarter

- Allenex acquired all minority holdings in the group from SSP Primers AB for a consideration of SEK 20 million, as well as paying back a loan of SEK 4 million. 2014 profit generated Olerup SSP AB and Olerup International AB will be fully transferred to Allenex.

Significant events in the second quarter

- No significant events occurred in the reporting period.

Significant events after the balance sheet date

- No significant events occurred after the balance sheet date.

FINANCIAL POSITION, CASH FLOW AND FINANCING

Consolidated operating income for the first six months rose to SEK 10.0 million (6.2). The weakened Swedish krona has had a positive impact on revenues compared to last year as the majority of these are in EUR and USD. At the same time, the weak Swedish currency has had a negative impact on raw material and consumable costs as these are mainly purchased in EUR and USD.

Unrealized currency gains are included in other expenses, reducing these by SEK 2.0 million. Unrealized currency gains also boosted financial items by SEK 0.6 million. SEK 1.9 million of realized currency gains are also included in other expenses.

New product development expenses of SEK 7.7 million were capitalized, leaving a closing balance of SEK 10.5 million. The capitalization concerns the development of QTYPE™, a new product for HLA typing based on Real-Time PCR (qPCR) methodology.

The group's operations are financed by shareholders' equity and loans. Interest-bearing liabilities amounted to SEK 111.0 million (95.0). The consolidated equity/assets ratio was 57 percent (63). Consolidated equity was SEK 201.7 million (217.6), corresponding to SEK 1.68 per share (1.81). Equity decreased by SEK 20.0 million due to the acquisition of all minority holdings, and increased as the accrued interest of SEK 1 million was waived. Cash and cash equivalents totaled SEK 2.4 million (9.6).

Cash flow from operating activities before changes in working capital for the first six months was SEK 6.3 million (2.8). Unrealized currency gains of SEK 2.0 million are included in Ad-

justment for items not included in the cash flow. The investing activities includes investments in capitalized assets of SEK 7.7 million. The financing activities includes the acquisition of minority holdings of SEK 20.0 million less a debt to SSP Primers of SEK 14.0 million, net SEK 6.0 million and includes also a new bank loan of SEK 10.0 million, amortization of a bank loan of SEK 3.0 million as well the repayment of a loan to SSP Primers of SEK 4.0 million.

According to the agreement with SSP Primers AB during the first quarter, Allenex acquired 9.0 percent of Olerup SSP AB, 1.9 percent of Absorber AB, 25.0 percent of Olerup International AB as well as 50.0 percent of Olerup Inc. USA. Under the terms of the agreement, SSP Primers has waived any further claims on Allenex and the other companies in the group, among other things accrued interest. 2014 profit in Olerup SSP AB and Olerup International will be transferred to Allenex in full. The debt to SSP Primers AB will be paid in three installments of SEK 4.0 million (February 2016), SEK 5.0 million (February 2017) and SEK 5.0 million (February 2018). A fixed interest rate of 3 percent paid annually in arrears will be charged on the outstanding amount.

RISKS AND UNCERTAINTIES

Allenex has long been a well-established business with well-known products in the field of genomic HLA typing based on SSP technology, with a significant market share. At the same time, the company faces market risk in the form of competition from other producers, the transition to more automated typing processes as well as new technologies, which may make it difficult for the company to maintain market share and margins.

Operational risk is primarily tied to the company's ability to constantly update its product range and to produce continually updated HLA test kits in pace with market demand.

Products sold and distributed on the basis of cooperation agreements with other companies increase the opportunity of strengthening market position and profitability, while they also carry an increased risk in light of the commitments in terms of resource investments and costs resulting from such agreements. The SBT products from the Australian company Conexio Genomics in particular are expected to achieve significant sales. At the same time, this involves significant competition and market risk. The ability to deliver the right quality on time has both a short and long-term significance for the business. For example, the inability of the partner to deliver due to production downtime could have a substantial negative effect on sales. Allenex has committed to minimum purchasing level from Conexio.

The transplantation test XM-ONE® is primarily established as a research product for larger centers. Work is underway to get the product established in broad clinical use. This has proven to take longer than planned and there is a risk that the product may not attain the success anticipated. This in turn could have a negative on the value of the company's intangible assets and

other assets. To date, XM-ONE® is virtually alone in its field and has significant patent protection. However, work is ongoing at the company's competitors to establish similar testing methods. Therefore, there is a risk that the company's competitors may challenge the position that XM-ONE® has on the market.

The Allenex group has a significant exposure to exchange rate fluctuations due to the fact that most of the company's revenues are in EUR and USD, while costs are partly in SEK. This may signify a currency risk for the company. Allenex does not conduct currency hedging activities.

Attracting and maintaining qualified personnel for development, production, marketing, sales, logistics and administration is essential to group performance.

The value of the company is partly dependent on its ability to maintain and protect patents, other intellectual property rights and specific expertise. Patent protection for medical, medtech and biotech products can be uncertain and involve complex legal and technical issues. Patents must usually be sought and maintained in several jurisdictions, and issued patents may be challenged, invalidated and circumvented. For Allenex or its subsidiaries this may mean loss of or shortened patent protection, which in turn may mean that the company cannot prevent competitors from marketing similar products. The uncertainty associated with patents and patent litigation and other patent processes, may have a negative impact on the competitiveness of Allenex and its subsidiaries, which in turn may have a negative effect on their business.

Both clinical trials and the marketing and sales of products pose a significant risk in terms of product liability. When deemed necessary, the company obtains product liability insurance. No assurance can be given that insurance will cover future claims against Allenex or its subsidiaries.

In certain cases the company is dependent on approval through clinical trials or decisions from public authorities. There are no guarantees that the company will achieve satisfactory results in such trials, or that the required regulatory approval will be granted.

The group's customer relations are stable and long-term, with historically low credit losses. Credit evaluations are carried out on new customers. Credit risk is currently assessed as low, but any change in a negative direction could impact the company's results and financial position.

Part of the financing was raised at variable interest rates, therefore rising interest rates could lead to lower returns for the company, which in turn could affect the company's results and financial position. Based on the current circumstances, the group is of the opinion that it has sufficient liquidity to conduct its operations according to current plans. There is a risk that market conditions and sales will develop negatively, which may have a negative effect on liquidity. The group's ability to re-finance maturing loans may also be adversely impacted by group performance and overall conditions in the financial markets. The company's cash and cash equivalents are placed in liquid assets with low credit risk.

No significant changes in risk assessment have been made compared to the annual report 2014, pages 23-24.

FINANCIAL INSTRUMENTS

Allenex financial instruments consist of trade account receivable, cash and cash equivalents, trade accounts payable, accrued supplier expenses and interest-bearing liabilities. Liabilities to credit institutions have variable interest rates. Liabilities to shareholders and SSP Primers AB have fixed interest rates, which essentially correspond to current market rates. Other financial assets and liabilities have short life spans. The fair value of all financial instruments is deemed to approximate the book value. Allenex has not netted any financial assets or liabilities and has not entered into any offset agreements.

RELATED PARTY TRANSACTIONS

Transactions with related parties are detailed in Note 10 of the Allenex 2014 Annual Report. No substantial change has occurred in the content or scope of these transactions for the period.

PARENT COMPANY

Revenues for the period amounted to SEK 1.4 million (1.4). Operating loss for the period was SEK 7.0 million (-7.1). The company's long-term intragroup receivables amounted to SEK 158.0 million (97.7). Cash and cash equivalents were SEK 0.7 million (1.8). The parent company had a negative cash flow from operations of SEK 8.6 million (-7.6). At the period end the parent company had 4 employees (4).

THE SHARE AND SHAREHOLDERS

PRINCIPAL OWNERS 06/30/2015	NO. OF SHARES	OWNERSHIP STAKE %
Midroc Invest AB	43,678,850	36.3
FastPartner AB (publ)	38,886,307	32.3
Xenella Holding AB *)	11,174,755	9.3
Handelsbanken Liv **)	6,842,887	5.7
Avanza Pension	1,920,068	1.6
Handelsbanken Fonder	578,012	0.5
Other	17,207,569	14.3
TOTAL	120,288,448	100.0

*) Xenella Holding AB is jointly owned by Midroc Invest AB and FastPartner AB (publ).

**) Mannersons Fastigheter AB's holding as per April 14, 2015 was transferred to Handelsbanken Liv.

ACCOUNTING PRINCIPLES

Allenex applies International Financial Reporting Standards (IFRS) as adopted by the EU and the Swedish Annual Accounts Act. This interim report was prepared in accordance with IAS 34 and the Annual Accounts Act for the group and in accordance with the Annual Accounts Act for the parent company. The accounting principles and methods of calculation applied for

the group and the parent company are consistent with those used in the preparation of the most recent Annual Report.

FUTURE REPORT DATES

Interim Report January-September: November 27, 2015

Year-end report: February 25, 2016

The Board of Directors and the CEO certify that the half-year report gives a true and fair view of the company's operations, financial position and results and describes the significant risks and uncertainties faced by Allenex and its subsidiaries.

Stockholm, August 27, 2015

Anders Williamsson
Chairman of the Board

Oscar Ahlgren
Board member

Jan Eriksson
Board member

Sven-Olof Johansson
Board member

Gunnar Mattsson
Board member

Anders Karlsson
CEO

This interim report has not been subject to review by the company's auditors.

The information in this interim report is such that Allenex AB (publ) is required to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. This re-port and earlier financial reports are available at www.allenex.com

This information was released for publication on August 27, 2015 at 13.00 CET

Consolidated statement of comprehensive income

	2015	2014	2015	2014	2014
	APRIL-JUNE	APRIL-JUNE	JAN-JUNE	JAN-JUNE	JAN-DEC
Amounts in SEK thousand					
Net sales	33,850	31,527	67,551	62,082	125,216
Change in inventories	1,521	147	131	855	5,384
Capitalized work for own account	609	-	1,099	-	711
Other revenue	768	1,549	1,863	2,148	4,209
	36,748	33,223	70,644	65,085	135,520
Raw materials and consumables	-7,719	-7,564	-15,478	-12,560	-26,169
Other expenses	-11,330	-10,860	-18,058	-20,726	-38,850
Employee benefit expenses	-12,447	-12,225	-24,029	-24,545	-45,161
Depreciation/Amortization	-1,035	-555	-2,041	-1,081	-2,450
Operating results	4,217	2,019	10,038	6,173	22,890
Other financial expenses and income	-2,989	-914	-2,159	-2,550	-2,520
Results after financial items	1,228	1,105	7,879	3,623	20,370
Taxes	-858	-730	-1,963	-1,977	-5,182
Net income for the period	370	374	5,916	1,646	15,188
Other comprehensive results for the period					
Components that will not be reclassified to net income	-	-	-	-	-
Components that will be reclassified to net income	-	-	-	-	-
Translation differences	314	44	-5,689	71	-6,850
Comprehensive income for the period	684	419	227	1,717	8,338
Results for the period attributable to:					
Owners of the parent company	370	116	5,916	1216	12,918
Non-controlling interests	-	259	-	430	2,270
Comprehensive results for the period attributable to:					
Owners of the parent	684	581	227	1,399	10,228
Non-controlling interests	-	-161	-	318	-1,890
Earnings per share, basic and diluted, SEK	0.00	0.00	0.05	0.01	0.11
Average number of outstanding shares, basic and diluted	120,288,448	120,288,448	120,288,448	120,288,448	120,288,448
Number of shares at the period end	120,288,448	120,288,448	120,288,448	120,288,448	120,288,448

Consolidated statement of financial position

	2015	2014	2014
Amounts in SEK thousand	30 JUNE	30 JUNE	31 DEC
Assets			
Goodwill	215,029	215,600	215,272
Other intangible assets	70,830	62,991	64,776
Tangible assets	3,746	3,419	3,278
Deferred tax assets	3,099	6,009	4,170
<i>Total non-current assets</i>	<i>292,704</i>	<i>288,019</i>	<i>287,496</i>
Inventories	37,475	33,354	38,106
Current receivables	18,726	16,963	17,002
Cash and cash equivalents	2,448	9,623	7,323
<i>Total current assets</i>	<i>58,649</i>	<i>59,940</i>	<i>62,431</i>
<i>Total assets</i>	<i>351,353</i>	<i>347,959</i>	<i>349,927</i>
Equity and liabilities			
Equity	201,737	217,576	220,480
Interest-bearing non-current liabilities	95,000	80,381	71,324
Deferred tax liabilities	14,974	13,549	14,321
Interest-bearing current liabilities	15,962	14,626	20,923
Non-interest bearing current liabilities	23,680	21,827	22,879
<i>Total equity and liabilities</i>	<i>351,353</i>	<i>347,959</i>	<i>349,927</i>

Consolidated statement of changes in equity

	2015	2014	2014
Amounts in SEK thousand	30 JUNE	30 JUNE	31 DEC
Opening balance	220,480	215,859	215,859
Dividends paid to non-controlling interests	-	-	-3,717
Acquisition of minority holdings in subsidiaries	-18,970	-	-
Comprehensive results for the period	227	1,717	8,338
<i>Closing balance</i>	<i>201,737</i>	<i>217,576</i>	<i>220,480</i>
Of which attributable to:			
Owners of the parent company	201,737	226,099	231,210
Non-controlling interests	-	-8,522	-10,730

Consolidated statement of cash flow

	2015	2014	2014
Amounts in SEK thousand	JAN-JUNE	JAN-JUNE	JAN-DEC
Operating income	10,038	6,173	22,890
Adjustment for items not included in the cash flow	1,112	1,669	-3,832
Financial items	-1,190	-1,581	-3,012
Taxes paid	-737	-331	-504
<i>Cash flow from operations before changes in working capital</i>	<i>9,223</i>	<i>5,930</i>	<i>15,542</i>
Increase (-)/Decrease(+) in inventories	858	-3,278	-6,950
Increase (-)/Decrease(+) in operating receivables	-1,466	-2,378	1,072
Increase (-)/Decrease(+) in operating liabilities	-2,337	2,519	802
<i>Cash flow from operating activities</i>	<i>6,278</i>	<i>2,793</i>	<i>10,466</i>
Cash flow from investing activities	-8,690	-154	-3,235
Cash flow from financing activities	-3,000	-3,000	-9,717
<i>Cash flow for the period</i>	<i>-4 912</i>	<i>-361</i>	<i>-2,486</i>
Cash and cash equivalents at the start of the period	7,323	10,046	10,046
Exchange rate differences in cash and cash equivalents	37	-62	-237
<i>Cash and cash equivalents at the period-end</i>	<i>2,448</i>	<i>9,623</i>	<i>7,323</i>

¹⁾ The Investing activities post includes and investments in capitalized assets of SEK 7.7 million. The Financing activities post includes the acquisition of minority holdings of SEK 20 million less a debt to SSP Primers of SEK 14 million, net 6 million and a new bank loan of SEK 10 million, amortization of a bank loan of SEK 3.0 million as well the repayment of a loan to SSP Primers AB of SEK 4 million.

Parent company income statement

	2015	2014	2014
Amounts in SEK thousand	JAN-JUNE	JAN-JUNE	JAN-DEC
Revenues	1,375	1,375	2,749
Other external costs	-4,275	-3,619	-7,738
Personnel costs	-4,005	-4,782	-7,958
Depreciation/amortization	-54	-56	-109
Operating results	-6,959	-7,082	-13,056
Other financial expenses and income	-991	-975	-778
Results after financial items	-7,950	-8,057	-13,834
Appropriations			
Group contributions received	-	-	38,355
Group contributions paid	-	-	-17,158
Results before tax		-8,057	7,363
Taxes	0	0	0
Results for the period	-7,950	-8,057	7,363
Parent company statement of comprehensive income			
Results for the period	-7,950	-8,057	7,363
Other comprehensive results for the period	-	-	-
Comprehensive results for the period	-7,950	-8,057	7,363

Parent company balance sheet

	2015	2014
Amounts in SEK thousand	30 JUNE	31 DEC
Assets		
Tangible assets	106	150
Participations in group companies	77,378	57,378
Non-current intra-group receivables	157,980	96,003
Deferred tax assets	1,626	1,626
Total non-current assets	237,090	155,157
Current receivables	11,280	73,944
Cash and bank	718	91
Total current assets	11,998	74,035
Total assets	249,088	229,192
Equity and liabilities		
Equity	157,193	165,143
Non-current liabilities	30,000	19,609
Current liabilities	61,895	44,440
Total equity and liabilities	249,088	229,192
Changes in equity, parent company		
Opening balance	165,143	157,780
Results for the period	-7,950	7,363
Equity and liabilities	157,193	165,143

KEY FIGURES GROUP

	2015	2014
	JAN-JUNE	JAN-JUNE
Net sales, SEK thousand	67,551	62,082
Operating income, SEK thousand	10,038	6,173
Earnings after tax, SEK thousand	5,916	1,646
Earnings per share, basic and diluted, SEK	0.05	0.01
Equity per share, SEK	1.68	1.81
Equity/assets ratio, %	57	63
Return on equity, %	3	0
Average number of employees	56	55
Number of shares outstanding at the period-end	120,288,448	120,288,448
Average number of shares outstanding	120,288,448	120,288,448
Share price at the period-end, SEK	2.22	2.16
Market cap, SEK thousand	267,040	259,823

Definitions:

Earnings per share

Equity per share

Equity/assets ratio

Return on equity

Operating margin

Earnings after tax attributable to the parent company divided by the average number of outstanding shares.

Equity divided by the number of outstanding shares at the period end.

Equity at the period-end in relation to total assets.

Results attributable to parent company shareholders divided by equity attributable to the owners of the parent.

Earnings before financial items divided by net sales

For a more detailed glossary see annual report 2014, page 63

Companies in the Allenex Group

PRODUCTION AND R&D COMPANIES



Olerup SSP AB is world leading in the development of kits for genomic HLA typing, based on SSP technology. The product is used prior to a transplantation to match the donor and recipient. The better the match the lower the risk of complications following transplantation. HLA typing is a standard procedure prior to hematopoietic stem cell transplantation (bone marrow transplantation) and is also used in conjunction with organ transplants (kidney, lung, heart, etc.). In 2011, Olerup SSP entered into a five-year exclusive global agreement (excl. Australia, New Zealand and Taiwan) with Conexio Genomics, Perth, Australia. In 2014, the agreement was extended to April 2018. Allenex ownership stake in Olerup SSP AB is 100 percent. For more information visit www.olerup-ssp.com



AbSorber develops products that facilitate successful transplantation. AbSorber's transplantation test XM-ONE®, identifies antibodies that play a key role in rejection reactions. The company's research portfolio also includes a patented ABO column for transplantations between people of different blood groups and an ABO diagnostic test that measures the occurrence of blood group antibodies. Allenex ownership stake in AbSorber is 100 percent. For more information visit www.absorber.se

SALES & DISTRIBUTION COMPANIES



Olerup GmbH, based in Vienna, is responsible for sales, distribution and logistics in Europe and the rest of the world excluding North, Central and South America as well as the Nordic region. Sales encompass Olerup SSP's HLA typing products and AbSorber's XM-ONE® transplantation test. Furthermore, from mid-year 2011, the company also sells and distributes products from the Australian company Conexio Genomics. Sales are conducted by a proprietary sales team in Germany, Austria, Belgium, the Netherlands and Slovenia. Sales in other markets are handled by distributors. Allenex ownership stake in Olerup GmbH is 100 percent. For more information visit www.olerup.com



Olerup Inc., domiciled in West Chester, PA, USA, is responsible for the sales, distribution and logistics of Olerup SSP and AbSorber products. Furthermore, since mid-2011, the company sells and distributes products from the Australian company Conexio Genomics. The company has its own sales organization in the US, while sales in Canada and Central and South America are handled by distributors. Allenex ownership stake in Olerup Inc is 100 percent. For more information visit www.olerup.com